Yan Dong, PhD, School of Medicine
Despite the recent development and FDA approval of new hormone therapy drugs for metastatic castration-resistant prostate cancer, disease progression after hormone therapies remains the most critical challenge in the clinical management of prostate cancer. Emerging evidences indicate that prostate cancers can adapt to all current hormone therapies by signaling through constitutively-active androgen receptor splice variants that lack the ligand-binding domain. We are currently characterizing how these splice variants are generated and their mechanisms of action. We are also developing drugs/regimens to inhibit these splice variants for more effective treatment of advanced prostate cancer.
